CERVARIX: Clinical Trials

11 trials of CERVARIX, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 active not recruiting, 2 terminated. 11 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 411Completed 7, Active not recruiting 2, Terminated 2

Follow CERVARIX: new trials by email Literature Review of CERVARIX trials Research Report on CERVARIX

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine - Human Papillomavirus-Related Cervical Carcinoma
Phase 4Active not recruitingNational Cancer Institute (NCI)50002022-03-012026-10-22
Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine - Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
Phase 4Active not recruitingNational Cancer Institute (NCI)279452017-11-292025-09-04
FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program
CERVARIX, GARDASIL - Cervical Intraepithelial Neoplasia, HPV-Related Cervical Carcinoma
Phase 4CompletedInstituto Nacional de Salud Publica, Mexico30002017-01-032020-08-10
Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)
cervarix, Gardasil - Infection With Human Papillomavirus
Phase 4CompletedUniversity Hospital, Ghent122013-06-252022-12-09
Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults
Gardasil, Cervarix - HIV, Human Papillomavirus
Phase 4CompletedUniversity of Aarhus922011-08-012013-08-16
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil) - Infections, Papillomavirus, Papillomavirus Vaccines
Phase 4CompletedGlaxoSmithKline8732010-10-262020-07-21
Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination
Cervarix, Engerix-B - Human Papillomavirus Infection
Phase 4TerminatedNational Institute for Public Health and the Environment (RIVM)2010-09-012010-03-19
Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico
Bivalent Vaccines, Tetravalent Vaccine - Healthy
Phase 4CompletedInstituto Nacional de Salud Publica, Mexico20002009-11-012018-08-27
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
Cervarix, Gardasil - HPV Infections
Phase 4CompletedPublic Health England4002009-09-012020-10-01
A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.
Cervarix - Human Papillomavirus Infection Leading to Cervical Cancer
Phase 4TerminatedGlaxoSmithKline7432008-09-172019-11-05
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Cervarix, Engerix-B - Infections, Papillomavirus
Phase 4CompletedGlaxoSmithKline344122007-10-042019-11-15

Conditions studied

Papillomavirus Infections (5)  ·  Uterine Cervical Neoplasms (2)  ·  Uterine Cervical Dysplasia (1)

Sponsors

GlaxoSmithKline (3)  ·  Instituto Nacional de Salud Publica, Mexico (2)  ·  National Cancer Institute (NCI) (2)  ·  National Institute for Public Health and the Environment (RIVM) (1)  ·  Public Health England (1)  ·  University Hospital, Ghent (1)  ·  University of Aarhus (1)

Countries

Costa Rica (2)  ·  Mexico (2)  ·  Belgium (1)  ·  Brazil (1)  ·  Denmark (1)  ·  Estonia (1)  ·  Finland (1)  ·  India (1)  ·  Philippines (1)  ·  Thailand (1)  ·  United Kingdom (1)

Top investigators

Aimee R Kreimer (2)  ·  Aurelio Cruz, Valdez (1)  ·  Eduardo C Lazcano, Phd, MD (1)  ·  Geert Leroux-Roels, MD, PhD (1)  ·  Janet L. Pacheco (1)  ·  Lars Toft, MD (1)

Results publications

PMID 41276263, PMID 23650505, PMID 24273179, PMID 24355090, PMID 24553190, PMID 25593103, PMID 28319456, PMID 29055031, PMID 29845626, PMID 30085139, PMID 30926298, PMID 31736068, PMID 31829767, PMID 32078808, PMID 32161969, PMID 32574384, PMID 33639181, PMID 33857679, PMID 34097688, PMID 34857420, PMID 35649600, PMID 41337735

NIH funding

2017 (1)